UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Where are we now in biologic drugs for myositis?

Neves, Ana; Viveiros, Luísa; Venturelli, Veronica; Isenberg, David A; (2024) Where are we now in biologic drugs for myositis? Rheumatology , 63 (11) pp. 2938-2947. 10.1093/rheumatology/keae096. Green open access

[thumbnail of Isenberg_Biological drugs on myositis CLEAN COPY 8.12.23.pdf]
Preview
Text
Isenberg_Biological drugs on myositis CLEAN COPY 8.12.23.pdf

Download (294kB) | Preview

Abstract

Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of chronic autoimmune disorders. Up to 40% of IIM patients have long-term sequelae and significant functional disability. Its management can be challenging. New therapies are badly needed. The small number of cases with diverse presentations, and different diagnostic criteria interfere significantly with clinical trial results. Only intravenous immunoglobulin has been internationally approved for IIM patients. Most clinical trials of new biological therapies have failed to meet their primary endpoints in IIM, with only one biological drug recommended for refractory IIM treatment (rituximab), although not approved. We review several new emerging biological drugs including B cell depletion therapies, abatacept, janus-kinase inhibitors, and aldesleukin. Encouragingly, some phase II randomized controlled trials have evaluated the efficacy and safety of new biologics in IIM, demonstrating an improvement in clinical and laboratory measures.

Type: Article
Title: Where are we now in biologic drugs for myositis?
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/rheumatology/keae096
Publisher version: http://dx.doi.org/10.1093/rheumatology/keae096
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Idiopathic inflammatory myopathies, biological drugs, myositis treatment
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10188449
Downloads since deposit
Loading...
4Downloads
Download activity - last month
Loading...
Download activity - last 12 months
Loading...
Downloads by country - last 12 months
Loading...

Archive Staff Only

View Item View Item